在药物暴露已确认的小鼠结核模型中研究贝达喹啉、德拉马尼和莫西沙星联合方案(含或不含舒特唑胺)缩短治疗的潜力
研究在BALB/c小鼠结核模型中比较含贝达喹啉、德拉马尼和莫西沙星(BDM)方案(加或不加舒特唑胺)与标准HRZE方案的杀菌和灭菌活性。BDM方案1个月杀菌活性高于HRZE,3个月治疗时BDM方案组肺培养均阴性而HRZE组全部阳性,停药后复发率BDM方案低于HRZE。作者将结果转化至结核患者,认为BDMU方案较HRZE治疗可能缩短疗程25%。
要点
- B25D0.6M200U200在未感染BALB/c小鼠中产生人体等效暴露。
- 治疗1个月,B25D0.6M200U200和B25D0.6M200方案杀菌活性高于标准H10R10Z150E100方案。
- 治疗3个月,两种BDM方案组肺培养均阴性,而H10R10Z150E100组全部仍培养阳性。
核心结论
- 含BDM方案(含或不含舒特唑胺)在BALB/c结核模型中疗效高于HRZE方案,加用舒特唑胺有部分改善;作者将结果转化至结核患者,认为BDMU方案较HRZE治疗可能缩短疗程25%。
研究设计与样本
- 研究在BALB/c小鼠结核分枝杆菌感染标准模型中,于感染后3周开始治疗,评估B25D0.6M200U200、B25D0.6M200、B25D0.6M200(U2003)或H10R10Z150E100(异烟肼、利福平、吡嗪酰胺、乙胺丁醇,HRZE)方案的杀菌活性和复发率。
主要发现
- B25D0.6M200U200在未感染BALB/c小鼠中产生人体等效暴露。
- 治疗1个月后,B25D0.6M200U200和B25D0.6M200方案的杀菌活性高于标准H10R10Z150E100方案。
- 治疗3个月后,两种BDM方案组肺培养均阴性,而H10R10Z150E100组全部小鼠仍培养阳性。
- 治疗3个月后,B25D0.6M200U200组7%小鼠复发,B25D0.6M200组13%复发,H10R10Z150E100组40%复发,显示两种BDM方案灭菌活性增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: New and shorter regimens against multi-drug resistant tuberculosis (TB) remain urgently needed. To inform treatment duration in clinical trials, this study aimed to identify human pharmacokinetic equivalent doses, antimycobacterial and sterilizing activity of a novel regimen, containing bedaquiline, delamanid, moxifloxacin and sutezolid (BDMU), in the standard mouse model (BALB/c) of Mycobacterium tuberculosis (Mtb) infection. METHODS: Treatment of mice with B25D0.6M200U200, B25D0.6M200, B25D0.6M200(U2003) or H10R10Z150E100 (isoniazid, rifampicin, pyrazinamide, ethambutol, HRZE), started 3 weeks after Mtb infection. Bactericidal activity was assessed after 1, 2, 3 and 4 months of treatment and relapse rates were assessed 3 months after completing treatment durations of 2, 3 and 4 months. RESULTS: B25D0.6M200U200 generated human equivalent exposures in uninfected BALB/c mice. After 1 month of treatment, a higher bactericidal activity was observed for the B25D0.6M200U200 and the B25D0.6M200 regimen compared to the standard H10R10Z150E100 regimen. Furthermore, 3 months of therapy with both BDM-based regimens resulted in negative lung cultures, whereas all H10R10Z150E100 treated mice were still culture positive. After 3 months of therapy 7% and 13% of mice relapsed receiving B25D0.6M200U200 and B25D0.6M200, respectively, compared to 40% for H10R10Z150E100 treatment showing an increased sterilizing activity of both BDM-based regimens. CONCLUSIONS: BDM-based regimens, with and without sutezolid, have a higher efficacy than the HRZE regimen in the BALB/c model of TB, with some improvement by adding sutezolid. By translating these results to TB patients, this novel BDMU regimen should be able to reduce treatment duration by 25% compared to HRZE therapy.
引用
- Walter K, Te Brake LHM, Lemm AK, et al. Investigating the treatment shortening potential of a combination of bedaquiline, delamanid and moxifloxacin with and without sutezolid, in a murine tuberculosis model with confirmed drug exposures. J Antimicrob Chemother. 2024. PMID: 39110473. doi:10.1093/jac/dkae266
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。